IP Library › Granted Patent US 11,078,267
Granted Patent B2
US 11,078,267 · App. 16/677,120 · Granted Aug 3, 2021

Method for treating lupus by administering an anti-IL-12 antibody

Inventors: Jill Giles-Komar (Downingtown, PA); David M. Knight (Berwyn, PA); David Peritt (Lake Forest, IL); Bernard Scallon (Wayne, PA); David Shealy (Downingtown, PA)
Assignee: Janssen Biotech, Inc.
C07K16/244A61K39/3955A61K45/06A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,078,267
App. No.
16/677,120
Granted
Aug 3, 2021
Kind
B2
Abstract

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.

Claims (4)

1. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering to said animal (i) a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, and (ii) a composition comprising an effective amount of an anti-rheumatic.

2. The method of claim 1 , wherein said effective amount of antibody is 0.001-50 mg/kilogram of said animal.

3. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering to said animal (i) a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain complementarity determining region CDR 1 of the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 3, a light chain CDR1 of the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 of the amino acid sequence of SEQ ID NO: 6, and (ii) a composition comprising an effective amount of an anti-rheumatic.

4. The method of claim 3 , wherein said effective amount of antibody is 0.001-50 mg/kilogram of said animal.

Continuity (14)
Division 16284316 · Feb 25, 2019
Division 15583487 · May 1, 2017
Division 15198678 · Jun 30, 2016
Division 14190893 · Feb 26, 2014
Division 13670918 · Nov 7, 2012
Division 13299874 · Nov 18, 2011
Division 12971626 · Dec 17, 2010
Division 12500120 · Jul 9, 2009
Division 11668256 · Jan 29, 2007
Division 10975883 · Oct 28, 2004
Division 09920262 · Aug 1, 2001
Provisional Application 60223358 · Aug 7, 2000
Provisional Application 60236827 · Sep 29, 2000
Related Publication 20200062841A1 · Feb 27, 2020